구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 5개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv) Johnson & Johnson·BCMA × CD3 132 trials·t½ ~2–3 weeks at steady state | linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt) Regeneron·BCMA × CD3 24 trials·t½ IgG-like, supporting weekly then less frequent dosing | |||
|---|---|---|---|---|---|
Overview Program | Darzalex (daratumumab) | Tecvayli (teclistamab) | Lynozyfic (linvoseltamab) | Tocilizumab | Velcade |
Overview Company | Janssen | Johnson & Johnson | Regeneron | Roche / Genentech | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CD38 | BCMA × CD3 | BCMA × CD3 | Chronic Lymphocytic Leukemia | Breast Cancer |
Overview Indication | Multiple myeloma | Relapsed or refractory multiple myeloma | Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody | Multiple Myeloma (MM); Multiple Myeloma Refractory | Multiple Myeloma |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | Approved (flag incomplete) | Approved (flag incomplete) |
Positioning Key differentiator | Direct on-tumor + immunomodulatory effects | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. | Response-adapted schedule can stretch to q4w after a deep response, so the compare with Tecvayli is visit burden and CRS step-up, not the antigen. | novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity | — |
Positioning Known limitation | CD38 downregulation, high tumor burden, and impaired effector function after prior lines. | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. | BCMA loss or mutation, T-cell exhaustion, and prior BCMA-directed therapy. | resistance to first- and second-line therapies | — |
Positioning Development positioning | — | Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T. | Second approved BCMA engager after Tecvayli; dosing frequency is the operational split. | — | — |
MoA Mechanism | Daratumumab binds CD38 on plasma cells and other immune cells, inducing direct apoptosis, Fc-mediated ADCC/CDC, and immunomodulatory effects including depletion of CD38+ regulatory cells and enhanced T-cell clonality. | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. | Binds BCMA on myeloma cells and CD3 on T cells, forming a cytolytic synapse that kills the plasma cell independent of native TCR specificity. | checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo | Targeting the mevalonate pathway |
MoA Biomarker | CD38 expression on clonal plasma cells (universal in MM). | BCMA expression, MRD negativity, serum free light chain response. | BCMA expression is not a companion diagnostic; soluble BCMA is exploratory. | biomarker for predicting treatment response in RA patients | Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients |
PK/PD Half-life | 20 h | ~2–3 weeks at steady state | IgG-like, supporting weekly then less frequent dosing | 3.4 h | 193 days |
PK/PD Species | Mouse, Human, M-protein, FLC, minimal residual disease, immunophenotypic CD38 saturation | Cynomolgus monkey, T-cell activation markers, cytokine profile, soluble BCMA | ORR, MRD, soluble BCMA | Rat | Mouse |
PK/PD Animal (cat.) | Human, Mouse | Human, NHP | Human | Rat, In vitro | Mouse, In vitro |
PK/PD Experiment | pd | pharmacokinetic | — | pd | tumor growth inhibition |
Toxicology Species | Cynomolgus monkey, Mouse, Human | Mouse | — | Rat | Mouse |
Toxicology Animal (cat.) | NHP | — | — | Rat, In vitro | Mouse, In vitro |
Toxicology Major finding | Infusion-related reactions (premedication required), cytopenias, and increased infection risk; subcutaneous formulation reduces IRR rate. | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Boxed warning for CRS and neurologic toxicity including ICANS. Neutropenia, infection, and hypogammaglobulinemia dominate later cycles. | Interstitial Lung Disease: A Case Report | thrombocytopenia (50%); the grade 4 toxicities were thrombocytopenia (12 |
Toxicology CRS | N/A | CRS ~72%, grade ≥3 ~0.6% | CRS common, mostly grade 1–2 with step-up | Reported | — |
Clinical Safety signal | Infusion-related reactions (premedication required), cytopenias, and increased infection risk; subcutaneous formulation reduces IRR rate. | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Boxed warning for CRS and neurologic toxicity including ICANS. Neutropenia, infection, and hypogammaglobulinemia dominate later cycles. | Interstitial Lung Disease: A Case Report | thrombocytopenia (50%); the grade 4 toxicities were thrombocytopenia (12 |
Clinical Selected reported efficacy | ORR 35.3% | ORR 63% | ORR 70% | ORR 95% | ORR 73.9% |
Clinical Reported ORR | 35.3% | 63.0% | 70% | 95.0% | 73.9% |
Clinical Reported PFS | — | ~11.3 mo | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02990338 | MajesTEC-1 (NCT03145181 / NCT04557098) | LINKER-MM1 (NCT03761108) | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT02195479 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | — | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02990338 | NCT03145181 | NCT03761108 | NCT03677141 | NCT02195479 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 5개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | teclistamab (Tecvayli, JNJ-64007957, teclistamab-cqyv) Johnson & Johnson·BCMA × CD3 132 trials·t½ ~2–3 weeks at steady state | linvoseltamab (Lynozyfic, REGN5458, linvoseltamab-gcpt) Regeneron·BCMA × CD3 24 trials·t½ IgG-like, supporting weekly then less frequent dosing | |||
|---|---|---|---|---|---|
Overview Program | Darzalex (daratumumab) | Tecvayli (teclistamab) | Lynozyfic (linvoseltamab) | Tocilizumab | Velcade |
Overview Company | Janssen | Johnson & Johnson | Regeneron | Roche / Genentech | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | CD38 | BCMA × CD3 | BCMA × CD3 | Chronic Lymphocytic Leukemia | Breast Cancer |
Overview Indication | Multiple myeloma | Relapsed or refractory multiple myeloma | Relapsed or refractory multiple myeloma after ≥4 prior lines including a PI, an IMiD, and an anti-CD38 antibody | Multiple Myeloma (MM); Multiple Myeloma Refractory | Multiple Myeloma |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING | ACTIVE |
Overview Content status | Curated Core | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved | Approved (flag incomplete) | Approved (flag incomplete) |
Positioning Key differentiator | Direct on-tumor + immunomodulatory effects | No manufacturing slot needed, so it can be started immediately in rapidly progressing myeloma. | Response-adapted schedule can stretch to q4w after a deep response, so the compare with Tecvayli is visit burden and CRS step-up, not the antigen. | novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity | — |
Positioning Known limitation | CD38 downregulation, high tumor burden, and impaired effector function after prior lines. | BCMA loss, soluble BCMA acting as a sink, and T-cell exhaustion. | BCMA loss or mutation, T-cell exhaustion, and prior BCMA-directed therapy. | resistance to first- and second-line therapies | — |
Positioning Development positioning | — | Class-defining BCMA engager; competes with Elrexfio and BCMA CAR-T. | Second approved BCMA engager after Tecvayli; dosing frequency is the operational split. | — | — |
MoA Mechanism | Daratumumab binds CD38 on plasma cells and other immune cells, inducing direct apoptosis, Fc-mediated ADCC/CDC, and immunomodulatory effects including depletion of CD38+ regulatory cells and enhanced T-cell clonality. | Simultaneously engages BCMA on plasma cells and CD3 on T cells, forming an immune synapse that redirects polyclonal T cells to lyse BCMA+ myeloma cells independent of TCR specificity. | Binds BCMA on myeloma cells and CD3 on T cells, forming a cytolytic synapse that kills the plasma cell independent of native TCR specificity. | checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo | Targeting the mevalonate pathway |
MoA Biomarker | CD38 expression on clonal plasma cells (universal in MM). | BCMA expression, MRD negativity, serum free light chain response. | BCMA expression is not a companion diagnostic; soluble BCMA is exploratory. | biomarker for predicting treatment response in RA patients | Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients |
PK/PD Half-life | 20 h | ~2–3 weeks at steady state | IgG-like, supporting weekly then less frequent dosing | 3.4 h | 193 days |
PK/PD Species | Mouse, Human, M-protein, FLC, minimal residual disease, immunophenotypic CD38 saturation | Cynomolgus monkey, T-cell activation markers, cytokine profile, soluble BCMA | ORR, MRD, soluble BCMA | Rat | Mouse |
PK/PD Animal (cat.) | Human, Mouse | Human, NHP | Human | Rat, In vitro | Mouse, In vitro |
PK/PD Experiment | pd | pharmacokinetic | — | pd | tumor growth inhibition |
Toxicology Species | Cynomolgus monkey, Mouse, Human | Mouse | — | Rat | Mouse |
Toxicology Animal (cat.) | NHP | — | — | Rat, In vitro | Mouse, In vitro |
Toxicology Major finding | Infusion-related reactions (premedication required), cytopenias, and increased infection risk; subcutaneous formulation reduces IRR rate. | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Boxed warning for CRS and neurologic toxicity including ICANS. Neutropenia, infection, and hypogammaglobulinemia dominate later cycles. | Interstitial Lung Disease: A Case Report | thrombocytopenia (50%); the grade 4 toxicities were thrombocytopenia (12 |
Toxicology CRS | N/A | CRS ~72%, grade ≥3 ~0.6% | CRS common, mostly grade 1–2 with step-up | Reported | — |
Clinical Safety signal | Infusion-related reactions (premedication required), cytopenias, and increased infection risk; subcutaneous formulation reduces IRR rate. | Boxed warning for CRS and neurologic toxicity including ICANS. Profound hypogammaglobulinemia and infection — including opportunistic infection — drive most late morbidity. | Boxed warning for CRS and neurologic toxicity including ICANS. Neutropenia, infection, and hypogammaglobulinemia dominate later cycles. | Interstitial Lung Disease: A Case Report | thrombocytopenia (50%); the grade 4 toxicities were thrombocytopenia (12 |
Clinical Selected reported efficacy | ORR 35.3% | ORR 63% | ORR 70% | ORR 95% | ORR 73.9% |
Clinical Reported ORR | 35.3% | 63.0% | 70% | 95.0% | 73.9% |
Clinical Reported PFS | — | ~11.3 mo | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02990338 | MajesTEC-1 (NCT03145181 / NCT04557098) | LINKER-MM1 (NCT03761108) | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT02195479 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | — | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT02990338 | NCT03145181 | NCT03761108 | NCT03677141 | NCT02195479 |
추천 비교
추천 비교